This two-year Fellowship Program in collaboration with Northeastern University and Alkermes plc is designed to offer Doctor of Pharmacy graduates an in-depth experience in a biopharmaceutical industry setting. Alkermes has a diversified portfolio of commercially available medications and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders (e.g. addiction, schizophrenia) and oncology.
Alkermes Medical Affairs strives to educate healthcare communities and decision makers on the value of our products through the generation and dissemination of scientifically rigorous, accurate, and unbiased clinical, economic, and health outcomes information, with the goal of advancing healthcare. We accomplish this by partnering with internal Alkermes colleagues to catalyze science and knowledge and by serving as a bridge between Alkermes and the healthcare community.
For questions regarding the fellowship or application process, please email PharmDfellowship@alkermes.com
In 2015, Alnylam Pharmaceuticals partnered with Northeastern University to offer a unique fellowship opportunity in the heart of Boston. The program set out to equip postdoctoral PharmDs with the skills necessary to develop the advanced medicines of the future, like RNAi. The goal was and remains the same: to cultivate the future leaders of biotechnology and allow fellows to pioneer new therapies for patients. Alnylam fellows are grounded in their core expertise area but utilize the fellowship’s flexibility to branch out and discover other opportunities throughout the organization with personalized rotations. Part of the backbone of the fellowship program is the Northeastern University teaching opportunities which allow fellows to share their knowledge in an educational setting. The Fellowship Program proudly offers 2-year positions in the following expertise areas: Medical Affairs, Medical Information, Value and Evidence Strategy/Health Economics and Outcomes Research (VESt/HEOR), Regulatory Affairs, Clinical Development, and Commercial.
At bluebird bio, we’re pioneering the uniquely promising world of gene therapy with a deep sense of purpose – with the goal that people will live their lives fully. To do it, we’re developing investigational gene therapies for severe genetic disease and cancer, while working to radically improve healthcare systems. Our ambition is to recode science, systems and the status quo – for life.
We are 1000+ employees with 4 locations across the US & Europe working towards 4 potential product approvals by 2022 and advancing a pipeline to tackle a range of severe diseases.
We pride ourselves on having a unique and caring culture that drives our success. A diverse flock of individual birds, we share common DNA that helps us build meaningful relationships with industry, patient & advocacy groups and the healthcare community.
blubird bio offers two year post-PharmD fellowships in Global Medical Affairs, with concentrations in Medical Information and Training and in Scientific Communications.
Blueprint Medicines offers a 2-year Fellowship Program in collaboration with Northeastern University designed to offer Doctor of Pharmacy graduates an in-depth experience in a biopharmaceutical industry setting. Blueprint Medicines is a global precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we combine our leading expertise in protein kinases with a uniquely targeted, scalable approach to empower the rapid design and development of transformational medicines.
Blueprint Medicines offers a two year post-PharmD fellowship in Global Medical Affairs.
Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis.
We embrace a philosophy of scientific entrepreneurship which spurs innovation and empowers and inspires our people to discover, develop and commercialize transformative therapies which can make a meaningful difference in the lives of patients.
The Flexion Medical Affairs team is dedicated to identifying, generating, communicating and gathering scientific knowledge of musculoskeletal conditions as trusted scientific colleagues and strategic business partners, ultimately improving the management of patients with these conditions.
Flexion offers a two year post-PharmD fellowship in Medical Affairs.
GSK Oncology is committed to the discovery and development of new and potentially life-changing therapies for patients with cancer. Our vision is for people with cancer to not only to live, but to live well, because we are delivering innovative and transformational medicines. GSK’s approach to oncology is focused on innovation in the areas of immuno-oncology, cell therapy, cancer epigenetics, synthetic lethality.
GSK offers two year post-PharmD fellowships in U.S. Medical Affairs, Global Medical Information, Global Regulatory Affairs, and Global Scientific Communications.
Ipsen Biopharmaceuticals, Inc. is launching a 2-year post-PharmD fellowship in U.S. Medical Affairs in collaboration with Northeastern University, School of Pharmacy.
Ipsen is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Our presence in North America dates back to 1976, and now includes Ipsen’s third global hub right in the heart of the leading global biotech ecosystem in Cambridge, Mass., where a fully integrated biopharmaceutical team across External Innovation and Partnering, R&D, Manufacturing and Commercial operations collaborates. With Ipsen’s expansion of its footprint in Cambridge, and new North America headquarters in Kendall Square, the group is building a sustainable innovation engine within the biotech community.
IPSEN offers two year post-PharmD fellowships in Medical Affairs.
Sanofi Genzyme is proud to partner with Northeastern University to offer fellowship positions in Medical Affairs and Regulatory Affairs. The first year, Fellows customize their experience with individualized elective rotations throughout various groups in the company, while remaining a vital member in their core expertise area. In the second year, Fellows focus on their primary function. Throughout the two years, Fellows also have responsibilities at Northeastern University, such as teaching PharmD students and participating in longitudinal research with faculty.
2021-23 Fellowship Positions: Not recruiting for this cycle.
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan.
Takeda has presence in approximately 80 countries, with leading positions in Japan and the U.S., respectively the third and first largest pharmaceutical markets in the world. Takeda will deliver highly innovative medicines and transformative care for more people globally.
Takeda offers 2 year post-PharmD fellowships in Medical Affairs.
Verastem Oncology™ is a biopharmaceutical company focused on developing therapies to improve the lives of patients diagnosed with cancer in ways that are truly meaningful to them. When it comes to combating cancer, we realize there are no “one size fits all” treatment approaches. We understand that every cancer lives in an intricate and complex micro-environment, creating significant unmet needs which must be addressed. It’s why we remain open to new ideas and selectively pursue science with the potential to make a significant impact for physicians, patients and their caregivers. Verastem Oncology™ has assembled a team of passionate leaders from the biopharmaceutical industry, bringing together their experiences of drug discovery, drug development and commercialization. With deep expertise, agility and purpose, we are identifying and advancing late-stage, first-in-class clinical assets to market.
Verastem Oncology™ offers 2-year post-Pharm.D. fellowships in Medical Affairs, Regulatory Affairs and Safety & Pharmcovigilence in collaboration with Northeastern University, School of Pharmacy.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.
We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 2,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development.
Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal.
Vertex offers 2-year post-PharmD fellowships in Clinical Pharmacology, Global Medical Affairs, and Global Regulatory Affairs in collaboration with Northeastern University’s School of Pharmacy.
Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Using PRISM, our proprietary discovery and drug development platform that enables the precise design, optimization and production of novel stereopure oligonucleotides, we aspire to develop best in class medicines across multiple therapeutic modalities. Our goal is to develop and commercialize disease-modifying medicines for genetically defined diseases with a high degree of unmet medical need. Our initial focus for our clinical development programs is in neurology. We are conducting clinical trials of our lead program in Duchenne muscular dystrophy (“DMD”) targeting exon 51 and our two lead programs in Huntington’s disease (“HD”). We are advancing three additional development programs, targeting exon 53 in DMD and C9ORF72 in amyotrophic lateral sclerosis and frontotemporal dementia.
New partnership under development.